急性T细胞白血病小鼠脾脏肿瘤特异性反应T细胞研究  

STUDY OF TUMORSPECIFIC RESPONSE T CELLS FROM ACUTE T LYMPHOCYTIC LEUKEMIA MOUSE

作　　者：魏代奎[1] 尤胜国[1] 李牧[1] 廖晓龙[1] 

机构地区：[1]中国医学科学院中国协和医科大学血液学研究所实验血液学国家重点实验室

出　　处：《中国免疫学杂志》1998年第4期264-267,共4页Chinese Journal of Immunology

基　　金：国家自然科学基金

摘　　要：应用可选择性杀灭的瘤细胞和淋巴瘤细胞混合培养的体外致敏方法，从急性Ｔ细胞（Ｌ６１５）白血病小鼠的脾细胞中建立了体外可培养的肿瘤特异性反应Ｔ细胞系（ＴＳＲＴｓ）。细胞表型分析和功能测定的结果表明，这些ＴＳＲＴｓ中是以表型ＣＤ４＋Ｔ细胞为主（占７５％以上）。对结合Ｌ６１５瘤细胞膜蛋白的硝酸纤维素薄膜颗粒的刺激呈特异性反应，并对Ｌ６１５瘤细胞刺激反应产生白细胞介素２。虽然体外缺乏急性溶细胞活性，但Ｗｉｎｎ’ｓ测定和继承性免疫治疗结果表明体内转输这些ＣＤ４＋为主的ＴＳＲＴｓ具有显著抗瘤活性，与ＣＹ联合可以明显延长Ｌ６１５白血病小鼠存活时间。お? In this study long-term culture tumorspecific Tcell lines were established from L615 leukemia mouse spleen cells using tumor cells which can be selectively eradicated in vitro and by periodic stimulation with irradiated tumor cells in the presence of low concentraction of IL2 in mixed lymphocytetumor culture. The results of cell phenotyping and function assay indicate that there were a predominantly L3T4+(CD4+)T cells(>75%) and that the TSRTs can be induced specific proliferative response to nitrocellulose particlebound membrane proteins of L615 cells and induced IL2 secretion to in vitro stimulation with irradiation L615 cells,although lack of acutec cytolytic activity,winns assay and adoptive chemoimmunotherapy revealed in vivo transfer of the CD4+ predominatly TSRTs possess antitumor activity,in conjunction with CY can obviously prolonged L615 leukemia mice survival.These studies demonstrate that CD4+ TSRTs may be a main effector cells in controlling development of virusassociated mouse leukemia.

关 键 词：白血病 T细胞 肿瘤特异性反应 TSRTs 免疫疗法 

分 类 号：R733.710.3[医药卫生—肿瘤]